Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

GNCA Genocea Biosciences

Watchlist
0.007
-0.001-12.50%
Close 12/01 16:00 ET
High
0.007
Open
0.001
Turnover
119.56
Low
0.001
Pre Close
0.008
Volume
73.80K
Market Cap
435.00K
P/E(TTM)
Loss
52wk High
1.480
Shares
58.78M
P/E(Static)
Loss
52wk Low
0.000
Float Cap
362.77K
Bid/Ask %
0.00%
Historical High
191.920
Shs Float
49.02M
Volume Ratio
2.81
Historical Low
0.000
Dividend TTM
--
Div Yield TTM
--
P/B
0.04
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.15%
Amplitude
79.75%
Avg Price
0.001
Lot Size
1
Float Cap
362.77K
Bid/Ask %
0.00%
Historical High
191.920
Shs Float
49.02M
Volume Ratio
2.81
Historical Low
0.000
Dividend TTM
--
P/B
0.04
Dividend LFY
--
Turnover Ratio
0.15%
Amplitude
79.75%
Avg Price
0.001
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
CEO: Mr. William D. Clark
Market: Pink Market
Listing Date: 02/05/2014
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist